TAMOXIFEN ( DrugBank: Tamoxifen )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 3 |
| 113 | Muscular dystrophy | 7 |
| 227 | Osler disease | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02166944 (ClinicalTrials.gov) | April 2014 | 9/6/2014 | Tamoxifen Treatment in Patients With Motor Neuron Disease | The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease | Amyotrophic Lateral Sclerosis;ALS Functional Ration Scale;TAR-DNA-binding Protein-43;Tamoxifen;mTOR | Drug: tamoxifen 40 mg daily for one year | Taipei Medical University Shuang Ho Hospital | NULL | Completed | 20 Years | 80 Years | All | 20 | Phase 1/Phase 2 | Taiwan |
| 2 | NCT01257581 (ClinicalTrials.gov) | March 2011 | 8/12/2010 | Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: creatine;Drug: tamoxifen | Nazem Atassi | ALS Therapy Alliance;State University of New York - Upstate Medical University | Completed | 18 Years | N/A | All | 60 | Phase 2 | United States |
| 3 | NCT00214110 (ClinicalTrials.gov) | January 2001 | 13/9/2005 | Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS] | Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS] | Amyotrophic Lateral Sclerosis (ALS) | Drug: Tamoxifen | University of Wisconsin, Madison | NULL | Completed | 18 Years | 90 Years | Both | 100 | Phase 2 | United States |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004554-42-FR (EUCTR) | 26/03/2020 | 17/08/2018 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Tamoxifen 20mg Hexal® Filmtabletten INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 100 | Phase 3 | France;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland | ||
| 2 | EUCTR2017-004554-42-GB (EUCTR) | 29/01/2019 | 03/08/2018 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trialTamoxifen in Duchenne muscular dystrophy: A 48-week open labelextension of a multicentre, randomised, double-blind, placebo-controlled,phase 3 safety and efficacy trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Tamoxifen 20mg Hexal® Filmtabletten INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 100 | Phase 3 | France;Belgium;Spain;Netherlands;Germany;Switzerland;United Kingdom | ||
| 3 | EUCTR2017-004554-42-ES (EUCTR) | 22/01/2019 | 17/09/2018 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy - TAMDMD A multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: TAMOX INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland | ||
| 4 | EUCTR2017-004554-42-NL (EUCTR) | 16/01/2019 | 02/10/2018 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy - TAMDMDA multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: TAMOXIFEN INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 100 | Phase 3 | France;Belgium;Spain;Turkey;Germany;Netherlands;United Kingdom;Switzerland | ||
| 5 | NCT03354039 (ClinicalTrials.gov) | June 12, 2018 | 10/10/2017 | Tamoxifen in Duchenne Muscular Dystrophy | Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial | Duchenne Muscular Dystrophy | Drug: Tamoxifen;Drug: Matching placebo | University Hospital, Basel, Switzerland | NULL | Completed | 78 Months | 16 Years | Male | 93 | Phase 3 | France;Germany;Netherlands;Spain;Switzerland;United Kingdom |
| 6 | EUCTR2017-004554-42-DE (EUCTR) | 27/07/2018 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week open label extension of a multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Tamoxifen 20mg Hexal® Filmtabletten INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | NA | Female: no Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | France;Belgium;Spain;Turkey;Netherlands;Germany;United Kingdom;Switzerland | |||
| 7 | EUCTR2017-004554-42-BE (EUCTR) | 30/04/2019 | The study examines boys suffering from Duchenne muscular dystrophy. We are carrying out this study to examine the effect and tolerance of Tamoxifen in this disease. | Tamoxifen in Duchenne muscular dystrophy:A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trialTamoxifen in Duchenne muscular dystrophy: A 48-week open label extension of a multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy trial | Duchenne muscular dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Tamoxifen 20mg Hexal® Filmtabletten INN or Proposed INN: Tamoxifen Other descriptive name: TAMOXIFEN CITRATE | University of Basel Children's Hospital, Division of Neuropediatrics | NULL | NA | Female: no Male: yes | 100 | Phase 3 | France;Spain;Belgium;Turkey;Netherlands;Germany;United Kingdom;Switzerland |
227. Osler disease
Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00375622 (ClinicalTrials.gov) | February 2005 | 12/9/2006 | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Tamoxifen | Rabin Medical Center | NULL | Completed | 18 Years | N/A | Both | 60 | Phase 2 | Israel |